



Supplementary Figure 1. A. Schema for generation of CRC cell lines resistant to KRAS G12C and EGFR inhibitors. Cells were grown in increasing doses of sotorasib with 50 $\mu\text{g}/\text{mL}$ cetuximab. B. Growth curves for parental and resistant subline of C106 treated with increasing doses of sotorasib and cetuximab. Experiments were done with average of 3 independent biological replicates each one of those having 3 technical replicates. Standard deviation indicated with error bars. C. Growth curves for parental and resistant subline of RW7213 treated with increasing doses of sotorasib and cetuximab. Experiments were done with average of 3 independent biological replicates each one of those having 3 technical replicates. Standard deviation indicated with error bars. D. Western blot analysis of signaling effect of sotorasib and cetuximab exposure for 4 hours in C106 parental and resistant sublines. E. Western blot analysis of signaling effect of sotorasib and cetuximab exposure for 4 hours in RW7213 parental and resistant sublines.